HUE061450T2 - 1-ciano-2-(4-ciklopropil-benzil)-4-(béta-d-glükopiranosz-1-il)-benzol és L-prolin kristályos monohidrát komplexe kristályvízben (1:1:1), módszerek elõállítása és SGLT-inhibitorként való alkalmazása - Google Patents

1-ciano-2-(4-ciklopropil-benzil)-4-(béta-d-glükopiranosz-1-il)-benzol és L-prolin kristályos monohidrát komplexe kristályvízben (1:1:1), módszerek elõállítása és SGLT-inhibitorként való alkalmazása

Info

Publication number
HUE061450T2
HUE061450T2 HUE18155079A HUE18155079A HUE061450T2 HU E061450 T2 HUE061450 T2 HU E061450T2 HU E18155079 A HUE18155079 A HU E18155079A HU E18155079 A HUE18155079 A HU E18155079A HU E061450 T2 HUE061450 T2 HU E061450T2
Authority
HU
Hungary
Prior art keywords
glucopyranos
proline
cyclopropyl
cyano
beta
Prior art date
Application number
HUE18155079A
Other languages
English (en)
Hungarian (hu)
Inventor
Matthias Eckhardt
Tanja Maria Butz
Frank Himmelsbach
Hans-Juergen Martin
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of HUE061450T2 publication Critical patent/HUE061450T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04Carbocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
HUE18155079A 2012-07-26 2013-07-25 1-ciano-2-(4-ciklopropil-benzil)-4-(béta-d-glükopiranosz-1-il)-benzol és L-prolin kristályos monohidrát komplexe kristályvízben (1:1:1), módszerek elõállítása és SGLT-inhibitorként való alkalmazása HUE061450T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12177944 2012-07-26

Publications (1)

Publication Number Publication Date
HUE061450T2 true HUE061450T2 (hu) 2023-07-28

Family

ID=48874313

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18155079A HUE061450T2 (hu) 2012-07-26 2013-07-25 1-ciano-2-(4-ciklopropil-benzil)-4-(béta-d-glükopiranosz-1-il)-benzol és L-prolin kristályos monohidrát komplexe kristályvízben (1:1:1), módszerek elõállítása és SGLT-inhibitorként való alkalmazása

Country Status (23)

Country Link
US (1) US9145434B2 (https=)
EP (3) EP4166548A1 (https=)
JP (2) JP6538556B2 (https=)
CN (2) CN108774200A (https=)
AR (1) AR091908A1 (https=)
AU (1) AU2013294947B2 (https=)
BR (1) BR112015001327B1 (https=)
CA (1) CA2878698C (https=)
DK (2) DK2877460T3 (https=)
EA (2) EA201600506A1 (https=)
ES (2) ES2694675T3 (https=)
FI (1) FI3351539T3 (https=)
HR (2) HRP20230081T1 (https=)
HU (1) HUE061450T2 (https=)
LT (1) LT3351539T (https=)
MX (1) MX357906B (https=)
PL (2) PL2877460T3 (https=)
PT (2) PT2877460T (https=)
RS (1) RS63881B1 (https=)
SG (1) SG11201500574QA (https=)
SI (2) SI2877460T1 (https=)
TW (1) TW201418275A (https=)
WO (1) WO2014016381A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
DK2981269T3 (da) 2013-04-04 2023-10-23 Boehringer Ingelheim Vetmedica Gmbh Behandling af stofskifteforstyrrelser hos hestedyr
MX376097B (es) * 2013-12-17 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de sglt2 para usarse en el tratamiento o prevención de trastornos metabólicos en animales felinos.
CA2932674C (en) * 2014-01-23 2023-01-24 Boehringer Ingelheim Vetmedica Gmbh Treatment of metabolic disorders in canine animals
FI3721882T3 (fi) 2014-04-01 2024-09-24 Boehringer Ingelheim Vetmedica Gmbh Aineenvaihduntahäiriöiden hoito hevoseläimissä
CN103965020B (zh) * 2014-05-06 2015-09-09 启东东岳药业有限公司 制备5-碘-2-溴苄醇的方法
EP4403230A3 (en) 2014-09-25 2025-01-08 Boehringer Ingelheim Vetmedica GmbH Combination treatment of sglt2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
KR20170060035A (ko) * 2014-09-30 2017-05-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 나트륨 글루코스 공동운반체 2 억제제의 l- 프롤린 화합물, 및 l- 프롤린 화합물의 모노하이드레이트 및 결정
CZ2015110A3 (cs) * 2015-02-18 2016-08-31 Zentiva, K.S. Pevné formy empagliflozinu
AU2016310535B2 (en) 2015-08-27 2021-08-19 Boehringer Ingelheim Vetmedica Gmbh Liquid pharmaceutical compositions comprising SGLT-2 inhibitors
WO2017203457A1 (en) * 2016-05-26 2017-11-30 Dr. Reddy's Laboratories Limited Solid state forms of empagliflozin
WO2017206827A1 (zh) * 2016-05-28 2017-12-07 山东轩竹医药科技有限公司 钠-葡萄糖协同转运蛋白2抑制剂的晶型
MX2020006387A (es) 2017-12-19 2020-09-03 Boehringer Ingelheim Vetmedica Gmbh Sintesis del cocristal 1:1:1 de 1-ciano-2-(4-ciclopropil-bencil)-4 -(beta-d-glucopiranos-1-il)-benceno, l-prolina y agua.
EP4064854A1 (en) 2019-11-28 2022-10-05 Boehringer Ingelheim Vetmedica GmbH Use of sglt-2 inhibitors in the drying-off of non-human mammals
JP7423800B2 (ja) 2020-02-17 2024-01-29 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー ネコにおける心臓疾患の予防および/または治療のためのsglt-2阻害剤の使用
MX2024001184A (es) 2021-07-28 2024-02-27 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos.
CN117715639A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于预防和/或治疗非人哺乳动物中的肾脏病的用途
US20240269105A1 (en) 2021-07-28 2024-08-15 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023227492A1 (en) 2022-05-25 2023-11-30 Boehringer Ingelheim Vetmedica Gmbh Aqueous pharmaceutical compositions comprising sglt-2 inhibitors
JP2026508912A (ja) 2023-03-06 2026-03-13 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 液体医薬組成物、特に1種又は複数のsglt-2阻害剤を含む液体医薬組成物の送達のためのシステム
AU2024264357A1 (en) 2023-04-24 2025-10-09 Boehringer Ingelheim Vetmedica Gmbh Crystalline complexes between velagliflozin and selected co-crystal forming agents, methods for their preparation and the use thereof for preparing medicaments
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
CN121175053A (zh) 2023-05-24 2025-12-19 勃林格殷格翰动物保健有限公司 包含一或多种sglt-2抑制剂及替米沙坦的非人类哺乳动物中肾脏疾病和/或高血压的组合治疗和/或预防

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083066A2 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
BR0317929A (pt) * 2003-01-03 2006-04-11 Bristol Myers Squibb Co métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila
ATE557013T1 (de) * 2004-03-16 2012-05-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
TW200745075A (en) * 2005-09-08 2007-12-16 Boehringer Ingelheim Int Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
WO2007093610A1 (en) * 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es) * 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
US7919598B2 (en) * 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
TW200817424A (en) 2006-08-04 2008-04-16 Daiichi Sankyo Co Ltd Benzylphenyl glucopyranoside derivatives
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
CN101754972A (zh) * 2007-05-18 2010-06-23 百时美施贵宝公司 Sglt2抑制剂的晶体结构及其制备方法
CN103319445B (zh) * 2007-12-27 2016-01-20 阿斯利康公司 Sglt2抑制剂的晶体结构及其制备方法
MX2011001855A (es) * 2008-08-22 2011-03-24 Theracos Inc Procesos para la preparacion de inhibidores de sglt2.
MY155418A (en) 2008-08-28 2015-10-15 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US20100167988A1 (en) 2008-10-22 2010-07-01 Auspex Pharmaceuticals, Inc. Ethoxyphenylmethyl inhibitors of sglt2
WO2011153712A1 (en) * 2010-06-12 2011-12-15 Theracos, Inc. Crystalline form of benzylbenzene sglt2 inhibitor
US9145434B2 (en) 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
DK2981269T3 (da) 2013-04-04 2023-10-23 Boehringer Ingelheim Vetmedica Gmbh Behandling af stofskifteforstyrrelser hos hestedyr

Also Published As

Publication number Publication date
SI3351539T1 (sl) 2023-03-31
EA201600506A1 (ru) 2017-03-31
SI2877460T1 (sl) 2018-12-31
TW201418275A (zh) 2014-05-16
CA2878698A1 (en) 2014-01-30
MX2015000962A (es) 2015-04-16
AU2013294947B2 (en) 2017-03-30
EA201500038A1 (ru) 2015-07-30
BR112015001327A2 (pt) 2017-07-04
WO2014016381A1 (en) 2014-01-30
PL3351539T3 (pl) 2023-03-06
BR112015001327B1 (pt) 2022-08-16
DK2877460T3 (en) 2019-01-07
EA025438B1 (ru) 2016-12-30
PL2877460T3 (pl) 2019-04-30
US9145434B2 (en) 2015-09-29
EP3351539A1 (en) 2018-07-25
EP4166548A1 (en) 2023-04-19
LT3351539T (lt) 2023-02-10
JP2015522644A (ja) 2015-08-06
RS63881B1 (sr) 2023-02-28
EP2877460B1 (en) 2018-09-12
AU2013294947A1 (en) 2015-01-22
DK3351539T3 (da) 2023-01-30
EP3351539B1 (en) 2022-11-09
CN104470908A (zh) 2015-03-25
EP2877460A1 (en) 2015-06-03
PT3351539T (pt) 2023-01-17
ES2694675T3 (es) 2018-12-26
PT2877460T (pt) 2018-12-19
JP6538556B2 (ja) 2019-07-03
HRP20230081T1 (hr) 2023-03-17
SG11201500574QA (en) 2015-02-27
HRP20181972T1 (hr) 2019-01-25
FI3351539T3 (fi) 2023-02-19
US20140031540A1 (en) 2014-01-30
ES2937665T3 (es) 2023-03-30
AR091908A1 (es) 2015-03-11
MX357906B (es) 2018-07-30
CN108774200A (zh) 2018-11-09
CA2878698C (en) 2021-03-23
JP2018135384A (ja) 2018-08-30

Similar Documents

Publication Publication Date Title
HUE061450T2 (hu) 1-ciano-2-(4-ciklopropil-benzil)-4-(béta-d-glükopiranosz-1-il)-benzol és L-prolin kristályos monohidrát komplexe kristályvízben (1:1:1), módszerek elõállítása és SGLT-inhibitorként való alkalmazása
PL3110901T3 (pl) Zastosowanie r-1233 w cieczowych urządzeniach chłodzących
GB2491118B (en) Cannabinoids for use in the treatment of neuropathic pain
IL228967B (en) Heterocyclic compounds as kinase inhibitors
PT2667849T (pt) Composição efervescente em forma sólida para utilização em aplicações vaginais para o tratamento de infeções vaginais
IL231227A0 (en) Compounds and preparations as kit inhibitors - c
IL231226A0 (en) Compounds and preparations as kit inhibitors - c
IL232822B (en) Furinone hydrochloride derivative, its crystals, preparations containing it and its uses
PT2697218T (pt) Processo para preparação de compostos úteis como inibidores da sglt2
IL250337A0 (en) Preparations for use in the treatment of nephropathy and methods for their preparation
IL225352A0 (en) Process for the preparation of cdk-pan inhibitors according to formula (i) and intermediates in the preparation
ZA201308541B (en) Compounds for use in treatment of mucositis
GB2490246B (en) Use of compositions for growth and vigour in soybean
GB2490250B (en) Use of compositions for growth and vigour in cotton
GB2490240B (en) Use of compositions for growth and vigour in vegetables
GB201113009D0 (en) Improvements in and relating to fluid sample holders
IL212725A (en) Glycerol Preparation for Non-surgical Conjunctivochalysis
GB201105927D0 (en) Improvements in or relating to cold storage
GB201113134D0 (en) Improvements in or relating to cold storage
GB201105928D0 (en) Improvements in or relating to cold storage
GB201108916D0 (en) Improvements in or relating to cold storage
GB201105923D0 (en) Improvements in or relating to cold storage
GB201110660D0 (en) Improvements in or relating to cold storage
GB201105489D0 (en) Improvements in or relating to cold storage
GB201105929D0 (en) Improvements in or relating to cold storage